26 even board, one-sign crazy earn 130,000! Wantai Bio's new share market value advances into TOP20

Pharmaceutical Network June 11th, June 9th, the high-profile new pharmaceutical shares Wantai Biological after 26 consecutive ups and downs, opened a word of up and down board, as of the day's close, the market value of 62.9 billion yuan, one of the profits of more than 130,000 yuanIt is worth mentioning that Wantai Bio with a bright performance into the pharmaceutical stock TOP20At present, the A-share market, Hengrui Pharmaceuticals, Meirui Medical, Pharmaceutical Mingkang and other 7 pharmaceutical stock market value of more than 100 billion scale, and Kantai Biological, film, etcare expected to be among the hundreds of billions of market value ranks.
Pharmaceutical stock market value TOP20 statistics as of June 9 close Wantai Bio April 29 landed a-share, after harvesting 26 ups and downs, June 9 opened a word board, as of the day's close, the market value of 62.9 billion yuan, a rise of more than 15 times, has become the largest number of new shares this yearIt is worth mentioning that Wantai Bio with a bright performance into the pharmaceutical stock TOP20, ranked 14thAt present, the A-share market, Hengrui Pharmaceuticals, Meirui Medical, Pharmaceutical Mingkang and other 7 pharmaceutical stock market value of more than 100 billion scale, and Kantai Biological, film, etcare expected to be among the hundreds of billions of market value ranksSince this year, Changchun high-tech, Kantai biology, Zhifei biology, Meirui medical and other pharmaceutical stocks rose more than 50%.
Data show that The main business of Wantai Biological has in vitro diagnostic reagents, in vitro diagnostic instruments and vaccine research and development, production and sales, core products include HIV diagnostic reagents, viral hepatitis series diagnostic reagents.
On June 10, Wantai Bio issued an unusual volatility in stock trading and risk warning announcement, said that the company's stock price has recently increased significantly, from April 29 to June 9, 2020, has been up 27 consecutive trading days (including 25 consecutive gains and losses except the first day), a cumulative increase of 1557.14 percentOn June 9th, the turnover was 5,018 million, with a turnover rate of 82.18 percentIn particular, the company reminded investors to pay attention to the secondary market trading risks.
In addition, the company's new crown testing reagents are currently based on the light-emitting platform of the new coronavirus testing kit (double antigen sandwich method) to obtain the domestic medical device registration certificate, and the new crown testing reagent sales accounted for a small proportion of the company's overall revenue, the company's financial situation will not have a significant impactThe company's double-price cervical cancer vaccine (HPV2 price) is not long on the market, vaccine sales by marketing, consumer acceptance and other factors, the impact of vaccine sales on the company's profits there is uncertainty.
Source: Public Company Announcement, Oriental Wealth Network